Target intelligence / Profile preview

Gastric mucin glycoprotein

Molecular classification
Other (specifically: secreted gel-forming glycoprotein; mucin family)
01

Overview

Gastric mucus glycoproteins, known as gastric mucins, are high-molecular-weight, heavily O-glycosylated glycoproteins secreted by specialized epithelial cells in the stomach lining[2][4][6]. These mucins are responsible for the viscosity and gel-forming properties of gastric mucus, enabling it to form a thick protective layer that lubricates stomach contents and shields the underlying epithelium from acidic gastric juice and digestive enzymes, thereby preventing autodigestion[1][3]. Structurally, gastric mucins have a protein backbone with extensive O-linked glycan modifications, especially in their central domains rich in serine, threonine, and proline (“PTS” domains)[2][6]. The glycan structures can differ in disease states, impacting stomach health, with qualitative and quantitative changes associated with inflammation, tumorigenesis, and susceptibility to infection[2][4]. Mucins are essential components of the mucosal innate immune barrier and play a role in maintaining gastrointestinal homeostasis, but they are not considered a direct drug target, receptor, or enzyme themselves[4][6]. The mucin family includes several specific gene products (MUC1, MUC5AC, MUC6, etc.), but “gastric mucus glycoproteins” is not a canonical name for an individual therapeutic target, making the entry non-specific and potentially misleading[6][4].

Other names
Gastric mucusGastric mucinMucus glycoproteinGastric mucus glycoproteinGastric mucins
02

Biological functions

Lubrication of stomach contentsFormation of protective mucosal barrierDefense against autodigestion by gastric acid and peptidasesModulation of epithelial defense and innate immunity
03

Disease associations

Cancer (related to mucin gene dysregulation or glycosylation changes)Inflammation (role in gastric mucosal defense and response to injury)Infection (barrier to pathogens)Other (involvement in metaplasia, mucosal disease, and ulceration)
04

Safety considerations

Qualitative and quantitative mucin shifts may compromise mucosal protectionAltered mucin glycosylation is linked to disease susceptibility (e.g., cancer, infection)

Beyond the preview

Go deeper on Gastric mucin glycoprotein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric mucin glycoprotein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call